Upcoming Investor Conferences for Tenax Therapeutics
Tenax Therapeutics, Inc. (NASDAQ: TENX), a key player in the field of cardiopulmonary therapies, is excited to announce its participation in several upcoming investor conferences. This opportunity allows the company to showcase its innovative approach to developing novel treatments for pulmonary hypertension, a significant health challenge worldwide.
Conference Details
The following conferences will feature presentations by Tenax’s leadership team:
8th Annual Evercore Healthcare Conference
In this conference format, attendees can expect an engaging fireside chat. The presentation will be led by Chris Giordano, President & Chief Executive Officer, alongside Stuart Rich, M.D., Chief Medical Officer. This session is scheduled for December 2, 2025, at 4:15 p.m. ET.
Piper Sandler 37th Annual Healthcare Conference
On December 4, 2025, at 11:30 a.m. ET, Chris Giordano and Stuart Rich will again be hosting a fireside chat at the Piper Sandler conference. These conversations aim to provide insights into the progress and future direction of Tenax Therapeutics.
Access to Presentations
For those interested in learning more about Tenax Therapeutics’ strategies and developments, live and archived webcasts of these presentations will be made available on the Company's investor relations webpage. This is a valuable chance for investors and interested parties to catch up on the key messages conveyed during these engagements.
About Tenax Therapeutics
Tenax Therapeutics is committed to addressing critical unmet medical needs through its research and development efforts. As a Phase 3, development-stage pharmaceutical company, it specializes in creating novel therapies aimed at treating various forms of pulmonary hypertension. The centerpiece of its pipeline is levosimendan, a promising candidate intended for the treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF). To date, levosimendan has not received approval for this condition, making Tenax's work vital.
The company’s innovative spirit, combined with a passionate team, drives its mission to enhance patient outcomes globally. As Tenax Therapeutics continues its journey, it remains focused on maximizing its potential and delivering effective treatments for patients in need.
Contact Information
For more information or inquiries, investors and media representatives can reach out to Argot Partners at tenax@argotpartners.com. The engagement with the media is part of Tenax's commitment to transparency and open communication with its stakeholders.
Frequently Asked Questions
What is Tenax Therapeutics?
Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on creating cardiopulmonary therapies.
What are the upcoming investor conferences?
The company will present at the Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler Healthcare Conference on December 4, 2025.
How can I access the webcasts of the presentations?
Live and archived webcasts will be available on Tenax’s investor relations webpage.
What is the main focus of Tenax's research?
Tenax Therapeutics primarily focuses on developing therapies for pulmonary hypertension, particularly for patients with PH-HFpEF.
Who can I contact for more information?
Queries can be directed to Argot Partners at tenax@argotpartners.com for media and investor inquiries.
